Research Progress of Solid Lipid Nanoparticles

doi:10.3969/j.issn.2095-1396.2017.06.003

Abstract

Abstract:

Solid lipid nanoparticles （SLN） is a solid colloidal drug delivery system based on natural or synthetic solid lipids embedded in lipophilic nuclei or coated on lipopolipid surfaces. The particle size of SLN is 10~1 000 nm. The carriers used in solid lipid nanoparticles are lipid-like compounds with low toxicity，good biocompatibility and biodegradability. It is a new generation of submicron drug delivery system developed in the early 1990s. Solid lipid nanoparticles have the advantages of controlling drug release，avoiding drug degradation or leakage，and good targeting. This paper summarized and analyzed the research progress of solid lipid nanoparticles，including the basic components，preparation methods，factors affecting drug loading （DL） and encapsulation efficiency （EE），drug delivery system release，the application and advantages of solid lipid nanoparticles.

Key words: solid lipid nanoparticles, carriers, targeting

CLC Number:

R944

GUO Tong-lin，WANG Cui，SHEN Li-xia. Research Progress of Solid Lipid Nanoparticles[J]. Acta Neuropharmacologica, DOI: 10.3969/j.issn.2095-1396.2017.06.003.

References

［1］ Christos Tapeinos, Matteo Battaglini, Gianni Ciofani. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases[J].Control Release, 2017, 264:306-332.

［2］ Rainer H MuÈller, Karsten MaÈder, Sven Gohla. Solid lipid nanoparticles (SLN) for controlled drugdelivery-a review of the state of the art[J].European J Pharmaceutics and Biopharmaceutics, 2000, 50(1): 161-177.

［3］ Peng Ji, Tong Yu, Ying Liu, et al. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics[J]. Drug Des Devel Ther, 2016, 10(1):911-925.

［4］ Paolo Blasi, Aur´elie Schoubben, Giovanna Valentina Romano, et al. Lipid nanoparticles for brain targeting II technological characterization[J]. Colloids and Surfaces B: Biointerfaces, 2013, 110:130-137.

［5］ Paolo Blasi, Stefano Giovagnoli, Aurélie Schoubben, et al. Solid lipid nanoparticles fortargeted brain drug delivery[J]. Adv Drug Deliv Rev, 2007, 59(6):454-477.

［6］ Donatella Paolino, Donato Cosco, Roberto Molinaro, et al. Supramolecular devices to improve the treatment of brain diseases[J].Drug Discov Today, 2011, 16(7-8): 311-324.

［7］ Giovanni Tosi, Luca Costantino, Barbara Ruozi, et al. Polymeric nanoparticles for the drug delivery to the central nervous system[J].Expert Opin Drug Deliv, 2008, 5(2): 155-174.

［8］ Ivana Cacciatore, Michele Ciulla, Erika Fornasari, et al. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases[J].Expert Opin Drug Deliv, 2016, 13(8): 1121- 1131.

［9］ Gregory Marslin, Karthik Siram, Xiang Liu, et al. Solid lipid nanoparticles of albendazole for enhancing cellular uptake and cytotoxicity against U-87 MG glioma cell lines[J]. Molecules, 2017, 22(11):2040.

［10］ Malgorzata Geszke-Moritz, Michal Moritz. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies[J].Mater Sci Eng C Mater Biol Appl, 2016, 68: 982-994.

［11］王婧雯, 汤海峰. 齐墩果酸固体脂质纳米粒的制备与质量评价[J]．第四军医大学学报, 2007, 28(5): 472-474．

［12］张卿, 张良珂, 袁佩, 等. 和厚朴酚固体脂质纳米粒的制备及性质研究[J].中草药, 2011, 42(4): 691-693.

［13］杨金枝, 孙文霞, 王姣姣, 等.白杨素固体脂质纳米粒的制备及其药动学行为[J].中成药, 2018, 40(1): 76-80.

［14］ Min Ji, Xiao-yuan Chen, Chien M Wai, et al. Synthensizing and dispersin silver nanoparticles in a water-in-supercritical carbon dioxide micromulsion[J]．Am Chem Soc, 1999, 121(11): 2631 -2632．

［15］胡英, 陈海靓, 梁文权. 槲皮素自乳化释药系统的制备和质量评价[J].中国中药杂志, 2007, 32(9): 805-807.

［16］张伟玲,刘晓娟. 槲皮素自微乳制剂的制备[J].山东大学学报:医学版, 2016, 54(3): 41-44.

［17］厉英超, 董蕾. 高压乳匀法制备中药固体脂质纳米粒[J]．南方医科大学学报, 2006, 26(5): 541-544.

［18］陈克玲, 郑瑞芳, 姜雯. 复方一枝蒿提取物固体脂质纳米粒的制备[J].中成药, 2018, 40 (9): 1949-1953.

［19］何瑶, 郭晓华. 依托泊苷固体脂质纳米粒的制备与抗癌活性研究[J].中国药师, 2018, 21(5): 792-796.

［20］ Alam Zeb, Omer S Qureshi, Hoo-Seong Kim, et al. High payload itra- conazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration[J]. J Pharm Pharmacol, 2017, 69(8): 955-966.

［21］孙陶利, 戴智, 蒋鹏程, 等. 阿魏酸川芎嗪固体脂质纳米粒制备及处方工艺优化[J].长沙医学院学报, 2018, 16(1): 7-11.

［22］ Vivek Makwana, Rashmi Jain, Komal Patel, et al. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach[J]. Int J Pharm, 2015, 495(1): 439-446.

［23］ Melike Uner, Gülgün Yener. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives[J]. Int J Nanomedicine, 2007, 2:289-300.

［24］ Sylvia A Wissing, Oliver Kayser, Rainer Helmut Müller. Solid lipid nanoparticles for parenteral drug delivery[J]. Adv Drug Deliv Rev, 2004, 56 :1257-1272.

［25］ Gian Paolo Zara, Alessandro Bargoni, Roberta Cavalli, et al. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats[J]. J Pharm Sci, 2002, 91:1324-1333.

［26］ Yang-chao Luo, Zi Teng, Ying Li, et al. Solid lipid nanoparticles for oral drug delivery: Chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake[J].Carbohydr Polym, 2015, 122: 221-229．

［27］ Carmelo Puglia, Paolo Blasi, Luisa Rizza, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation[J]. Int J Pharm, 2008, 357: 295-304.

［28］ Roberta Cavalli, M Rosa Gasco, Patrizia Chetoni, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin[J]. Int J Pharm, 2002, 238: 241-245.

［29］ Slavomira Doktorovová, Andjelka B Kova?evi?, Maria L Garcia, et al. Preclinical safety of solid lipidnanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation[J]. Eur J Pharm. Biopharm, 2016, 108: 235-252.

［30］杨时成, 朱家壁, 梁秉文, 等. 喜树碱固体脂质纳米粒的研究[J]. 药学学报, 1999, 34(2): 146-150.

［31］ João F Pinto. Preparation of administrated solid lipid nanoparticles using pellets as carrier[J]. Pharmazie, 1999, 54(7): 5-12.

［32］ Sabrina Weber, Andreas Zimmer, Jana Pardeike. Solid lipid nanoparticles (SLN) and nanostructuredlipid carriers (NLC) for pulmonary application: a review of the state of theart[J]. Eur J Pharm Biopharm, 2014, 86: 7-22.

［33］梅之南, 杨祥良, 杨亚江, 等. 雷公藤内酯醇固体脂质纳米粒经皮渗透及抗炎活性的研究[J].中国药学杂志, 2003, 38(11):38.

［34］ Roberta Cavalli, M Rosa Gasco, Patrizia Chetoni, et al. Solid lipidnanoparticles (SLN) as ocular delivery system fortobramycin[J]. Int J Pharm, 2002, 238(1-2): 241-245

［35］崔正云, 刘彬, 姜成哲, 等. 固体脂质纳米粒作为核酸疫苗载体的效应研究[J].东北农业大学学报, 2015, 46(8):15-20.

［36］ Nina Pedersen, Susan Hansen, Annette V Heydenreich, et al. Solid lipid nanparticles can effectively bind DNA, streptavidin and biotinylated ligands[J]. Eur J Pharm Biopharm, 2006, 62(2): 155-162.

［37］ Neda Naseri, Hadi Valizadeh, Parvin Zakeri-Milani. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application[J]. Adv Pharm Bull, 2015, 5: 305-313.

［38］ Stefan Wilhelm, Anthony J Tavares, Qin Dai, et al. Analysis of nanoparticle delivery to tumours[J]. Nat Rev Mater, 2016, 1(5): 16014.

［39］ Jinjin Shi, Philip W Kantoff, Richard Wooster, et al. Cancer nanomedicine: progress, challenges and opportunities[J].Nat Rev Cancer, 2016, 17: 20-37.

［40］ Ashwath Jayagopal, MacRae F Linton, Sergio Fazio, et al. Insights into atherosclerosis using nanotechnology[J].Curr Atheroscler Rep, 2010, 12: 209-215.

［41］ Mark E Lobatto, Valentin Fuster, Zahi A Fayad, et al. Perspectives and opportunities for nanomedicine in the management of atherosclerosis[J].Nat Rev Drug Discov, 2011, 10: 835-852.

［42］ Jennifer Sargent. Cardiovascular disease: New nanomedicines for treating atherosclero ticplaques[J].Nat Rev Endocrinol, 2015, 11: 256-256.

［43］ Xinlin Yang, Li Jin, Lu Yao, et al. Antioxidative nanofullerol prevents intervertebral disk degeneration[J]. Int J Nanomedicine, 2014, 9(1):2419-2430.

［44］ Li Jin, Meng-meng Ding, Azra Oklopcic, et al. Nanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides[J].Nanomedicine, 2017, 13: 2049-2059.

［45］ Tal Dvir, Michael Bauer, Avi Schroeder, et al. Nanoparticles targeting the infarcted heart[J].Nano Lett, 2011, 11: 4411-4414.

［46］ Sophia Suarez, Adah Almutairi, Karen L Christman. Micro- and nanoparticles for treating cardiovascular disease[J].Biomater Sci, 2015, 3:564-580.

［47］ Goo Yoon, Woo Park, In-Soo Yoon. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery[J]. Pharm Investig, 2013, 43(5): 353-362.

[1]	ZHANG Nan，ZHANG Dan-shen. Research Progress on Anticancer Effects and Dosage Forms of Osthole [J]. Acta Neuropharmacologica, 2017, 7(6): 22-29.
[2]	ZHAO Kai-yan1，ZHANG Dan-shen1，SU Xiao-mei1，ZHANG Hai-wei2，HOU Wen-shu2. Preparation and Characterization of Osthole Liposomes [J]. Acta Neuropharmacologica, 2017, 7(5): 21-.
[3]	ZONG Rui, SHEN Li-xia. Polymeric Micelles for Drug Delivery [J]. Acta Neuropharmacologica, 2015, 5(6): 21-29.
[4]	GAO Dong-xiao，ZHAO Ya-qun. Production of Microencapsulated Human Retinal Pigment Epithelial Cells by the High Voltage Electrostatic Method [J]. Acta Neuropharmacologica, 2011, 1(2): 24-27.